加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.9807
−US$0.0011 · -0.11%
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
常规交易时段
US$0.9807
−US$0.0011 · -0.11%
盘中时间采用ET。市场数据可能有所延迟。
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
日内区间
当前US$0.9807
52周区间
当前US$0.9807
盘中时间采用ET。市场数据可能有所延迟。
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
日内区间
当前US$0.9807
52周区间
当前US$0.9807
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 188.5万 USD | 1994.3万 USD | 1640.1万 USD | — |
| 销货成本 | 163.4万 USD | 181.4万 USD | 176.4万 USD | 251万 USD | — |
| 毛利 | −163.4万 USD | 7.1万 USD | 1817.9万 USD | 1389.1万 USD | — |
| 研究与开发 | 4483万 USD | 5643.4万 USD | 4177.6万 USD | 5376.1万 USD | 3526.9万 USD |
| 销售、一般及管理费用 | 1584.7万 USD | 1904.5万 USD | 1867万 USD | 2150.1万 USD | 1481.8万 USD |
| 营业费用 | 5904.3万 USD | 7366.5万 USD | 5868.2万 USD | 6994.7万 USD | 5008.7万 USD |
| 利息收入 | 310.8万 USD | 667.3万 USD | 741.6万 USD | 190.8万 USD | 10.4万 USD |
| 利息支出 | 527.4万 USD | 465.6万 USD | 313.9万 USD | — | — |
| 折旧和摊销 | 163.4万 USD | 181.4万 USD | 176.4万 USD | 110.4万 USD | 21.6万 USD |
| 营业利润 | −6067.7万 USD | −7359.4万 USD | −4050.3万 USD | −5605.6万 USD | −5008.7万 USD |
| 净利润 | −6082.2万 USD | −7051.5万 USD | −3736.8万 USD | −5381万 USD | −4998.3万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.50
上涨空间 562.79%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
